# A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma

> **NCT05698524** · PHASE1 · RECRUITING · sponsor: **University of Nebraska** · enrollment: 24 (estimated)

## Conditions studied

- Recurrent High Grade Glioma
- Anaplastic Astrocytoma
- Anaplastic Oligodendroglioma
- Glioblastoma
- Gliosarcoma

## Interventions

- **DRUG:** PCI 24781
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT05698524
- **Lead sponsor:** University of Nebraska
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-06-26
- **Primary completion:** 2027-07
- **Final completion:** 2029-07
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-04-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05698524

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05698524, "A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05698524. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*